Newsfeeds - Spark Newswire

1 minute read

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen

Today, 11:23 AM

Alkermes plc (NASDAQ:ALKS) commenced binding arbitration proceedings regarding two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE:JNJ). Under…

ALKS

2 minute read

Alkermes Commences Arbitration Related To License Agreements With Janssen Pharmaceutica

By Bill Haddad

Today, 11:23 AM

Alkermes plc (NASDAQ:ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson &

ALKS

4 minute read

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

By Shanthi Rexaline

Today, 11:23 AM

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

ACIU

2 minute read

Alkermes To Present Data On Nemvaleukin Alfa At Society Of Gynecologic Oncology 2022 Annual Meeting On Women’s Cancer Mar. 18-21

By Bill Haddad

Today, 11:23 AM

Alkermes plc (NASDAQ:ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at

ALKS

1 minute read

Alkermes’ Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer

By Vandana Singh

Today, 11:23 AM

Alkermes plc (NASDAQ: ALKS)

ALKS

2 minute read

Earnings

Alkermes’s Return On Capital Employed Overview

By Benzinga Insights

Today, 11:23 AM

According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31% increase since Q3.

ALKS

5 minute read

56 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:23 AM

Gainers

AERC

1 minute read

Why Are Alkermes Shares Trading Higher Today?

By Vandana Singh

Today, 11:23 AM

Alkermes plc's (NASDAQ: ALKS)

ALKS

3 minute read

40 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 11:23 AM

Gainers

AERC

1 minute read

UPDATE: Alkermes Q4 Adj. EPS $0.23 Beats $0.11 Estimate, Sales $324.46M Beat $308.69M Estimate

By Benzinga Newsdesk

Today, 11:23 AM

Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.11 by 109.09 percent. This is a 130 percent increase over earnings of $0.10 per share from the same

ALKS